LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength Tru Niagen® Pro 1,000mg, featuring 1,000mg of Niagen® (patented Nicotinamide Riboside or NR), one of the most efficient and superior quality NAD+ precursors on the market, to consumers nationwide.

洛杉矶-（商业线）-全球烟酰胺腺嘌呤二核苷酸（NAD+）研究和健康老龄化权威机构ChromaDex Corp.（纳斯达克股票代码：CDXC）推出其临床实力Truniagen®Pro 1000mg，具有1000mg向全国消费者提供市场上最有效和最优质的NAD+前体之一Niagen®（专利烟酰胺核苷或NR）。

With 1,000mg of Niagen used in over 50% of published clinical studies, this serving is redefining research for NAD+ related health outcomes..

在超过50%的已发表的临床研究中使用1000mg的烟碱，这项服务正在重新定义NAD+相关健康结果的研究。。

The most potent serving size of Niagen available for more pronounced healthy aging benefits, Tru Niagen Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to elevate NAD+ levels up to 150% in as little as three weeks. Tru Niagen Pro 1,000mg is Certified for Sport® by NSF International, which is the only third-party certification program recognized by the United States Anti-Doping Agency (USADA), Major League Baseball (MLB), and the National Hockey League (NHL)..

Niagen最有效的服务规模可用于更显着的健康老龄化益处，Tru Niagen Pro 1000mg由医生推荐并由专业运动员使用，因为临床证明在短短三周内将NAD+水平提高至150%。Tru Niagen Pro 1000mg获得NSF International体育认证，NSF International是美国反兴奋剂局（USADA），美国职业棒球大联盟（MLB）和国家曲棍球联盟认可的唯一第三方认证计划（NHL）。。

“On behalf of the ChromaDex family, we are proud to bring the clinical-strength benefits of our profound NAD+ boosting Tru Niagen to individuals across the nation,” comments Rob Fried, CEO of ChromaDex. “As a pioneer of NAD+ research, our team works with esteemed investigators across the globe to uncover the full potential of NAD+.

ChromaDex首席执行官Rob Fried评论说：“代表ChromaDex家族，我们很自豪地为我们深刻的NAD+提升Tru Niagen为全国各地的个人带来临床优势。“作为NAD+研究的先驱，我们的团队与全球尊敬的调查人员合作，揭示NAD+的全部潜力。

When using 1,000mg or more of Tru Niagen, researchers have discovered pronounced benefits in numerous age-related conditions.”.

当使用1000mg或更多的Tru Niagen时，研究人员在许多与年龄有关的疾病中发现了明显的益处。”。

Dr. Andrew Shao, Senior Vice President of Global Regulatory & Scientific Affairs, comments, “Research indicates that NAD+ decreases with age and, more specifically, that NAD+ levels are depressed in organs facing metabolic stress and age-related functional decline. 1,000mg is the most well-researched daily Niagen serving in published human studies, the results of which consistently demonstrate that elevated NAD+ levels correspond to a range of healthy aging benefits, including lowering age-related inflammation.”.

全球监管和科学事务高级副总裁Andrew Shao博士评论， “研究表明，NAD+随着年龄的增长而降低，更具体地说，NAD+水平在面临代谢应激和年龄相关功能下降的器官中受到抑制.1000mg是已发表的人类研究中研究最多的每日烟碱，其结果一致表明，升高的NAD+水平对应于一系列健康的衰老益处，包括lowering与年龄有关的炎症“。

As ChromaDex holds scientific rigor and quality to the highest standards, Tru Niagen is backed by two Nobel Prize winners, 25+ human clinical studies, 300 published scientific studies, has been accepted by the world’s most rigorous regulatory bodies and undergoes extensive quality testing for potency, safety and purity.

由于ChromaDex将科学严谨性和质量保持在最高标准，Tru-Niagen得到了两位诺贝尔奖获得者的支持，25项以上的人类临床研究，300项已发表的科学研究，已被世界上最严格的监管机构接受，并经过广泛的质量测试。效力，安全性和纯度。

Additionally, published clinical studies indicate that Niagen is safe to take up to 2,000mg per day..

此外，已发表的临床研究表明，Niagen每天可安全服用高达2000mg。。

Tru Niagen Pro 1,000mg was unveiled to a select group of Key Opinion Leaders (KOLs), physicians, influencers and celebrities at the Tru Niagen Wellness Retreat in Malibu last week. Guests learned about the health-altering power of Tru Niagen and NAD+ from a panel of leading experts including Dr. Aimee, OBGYN and Founder of The Egg Whisperer, Dr.

Tru Niagen Pro 1000mg上周在马里的Tru Niagen健康撤退地向一组精选的主要意见领袖（KOL），医生，影响者和名人揭晓。客人从一组领先的专家那里了解了Tru Niagen和NAD+的健康改变能力，这些专家包括Aimee博士，OBGYN博士和Egg Pellimer博士的创始人。

Darshan Shah, Founder of Next Health, Dr. Abe Malkin, Founder of Drip Hydration, Brooke Burke, Founder of Brooke Burke Body and Tru Niagen partner, Jennifer Cohen, Host of Habits & Hustle Podcast and Tru Niagen partner, Todd Anderson, Human Performance Coach and Owner of Dream Recovery, and Mona Rosene, MS, RD, Global Director of Scientific Affairs at ChromaDex & Tru Niagen..

Next Health的创始人Darshan Shah，Drip水合作用的创始人Abe Malkin博士，Brooke Burke的创始人Brooke Burke Body和Tru-Niagen的合作伙伴Jennifer Cohen，习惯与丈夫Podcast和Tru-Niagen的合作伙伴Todd Anderson，人类表现教练和梦想恢复的所有者，以及ChromaDex＆Tru-Niagen全球科学事务总监Mona Rosene，MS，RD。。

Tru Niagen Pro 1,000mg retails for $109.99 as a one-time purchase or $98.99 with a subscription at www.truniagen.com and will be available for $109.99 at www.amazon.com.

Tru Niagen Pro 1000mg零售价格一次性购买109.99美元，或通过www.truniagen.com订阅98.99美元，并将在www.amazon.com上以109.99美元的价格购买。

For additional information on the science supporting Niagen® visit www.chromadex.com.

有关支持Niagen®的科学的更多信息，请访问www.chromadex.com。

About ChromaDex:

关于ChromaDex：

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®.

ChromaDex Corp.是一家致力于健康老龄化的全球生物科学公司。包括世界知名科学家在内的ChromaDex团队正在对烟酰胺腺嘌呤二核苷酸（NAD+）进行开创性研究，其水平随着年龄的增长而下降。ChromaDex是NAD+前体烟酰胺核苷（NR）的创新者，作为旗舰成分Niagen®商业化。

Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company..

烟酰胺核苷和其他NAD+前体受ChromaDex专利组合的保护。ChromaDex在www.ChromaDex.com维护一个网站，ChromaDex定期向该网站发布其新闻稿的副本以及有关该公司的其他财务信息。。

Forward-Looking Statements:

前瞻性声明：

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to NR being the most efficient and superior NAD+ precursor on the market and whether the 1,000mg of Niagen will redefine research for NAD+ related health outcomes.

本版本包含1933年“证券法”（经修订）第27A条和1934年“证券交易法”（经修订）第21E条含义内的前瞻性声明，包括与NR有关的最有效和最优越的声明市场上的NAD+前体以及1000毫克的Niagen是否会重新定义NAD+相关健康结果的研究。

Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions.

不是对历史事实的描述的陈述构成前瞻性陈述，并且通常（但不总是）可以通过使用诸如“期望”，“预期”，“意图”，“估计”，“计划，“潜力”，“可能”，“可能”，“相信”，“寻求”，“可能”，“将会”，“应该”或这些术语或其他类似表达的否定。

Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition.

导致这些前瞻性声明性质不确定的风险包括COVID-19大流行对我们业务和全球经济的影响；我们的经营损失历史和需要获得额外融资；我们产品销售的增长和盈利能力；我们保持销售，营销和分销能力的能力；改变消费者对我们产品的看法；我们依赖单一或有限数量的第三方供应商；以及与我们的业务和财务状况相关的风险和不确定性。

More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.

有关ChromaDex的更详细信息以及可能影响实现前瞻性报表的风险因素，请参阅ChromaDex在截至2022年12月31日的财政年度10-K表格年度报告，ChromaDex关于表格10-Q的季度报告和ChromaDex向SEC提交的其他文件，其副本可从SEC网站www.SEC.gov获取。

Readers are cautioned not to place undue reliance on these forward-looking.

提醒读者不要过分依赖这些前瞻性。